Join
Live feed
·
PRReleasevia Quantisnow
Outlook Therapeutics Inc. logo

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

ByQuantisnow·Wall Street's wire, on your screen.
OTLK· Outlook Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OTLK (Outlook Therapeutics Inc.) and more on Quantisnow.